Biotronik completes patient enrolment for new study of Orsiro stent

Medical Company Product News

Biotronik has announced the completion of patient enrolment for BIOSTEMI, a new study assessing the benefits of its Orsiro stent in the treatment of heart attacks.

The trial is designed to evaluate the advantages of the Orsiro drug-eluting stent over the Xience Xpedition device among patients with ST-elevation myocardial infarction (STEMI), a potentially fatal type of heart attack caused by prolonged obstruction of blood supply in the heart.

“Biotronik has completed enrolment for a study assessing the benefits of the Orsiro stent in the treatment of a certain type of heart attack.“

In total, 1,250 patients have been enrolled across 16 study centres in Switzerland and Italy, with follow-up planned after five years. One-year results of the study will be presented at the EuroPCR 2019 conference.

This study is being launched after a significant difference was seen in the STEMI subgroup of the earlier BIOSCIENCE trial in a smaller cohort, with a favourable target lesion failure rate associated with Orsiro.

Dr Alexander Uhl, senior vice-president for corporate marketing at Biotronik, said: "After the extremely promising result of the BIOSCIENCE STEMI subgroup, we are confident that the BIOSTEMI trial will confirm Orsiro's effectiveness in the challenging STEMI indication."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news